Doxorubicin Market Size and Share Insights 2022 Industry Key Players with Growth Status, Revenue Expectations, and Regional Analysis Forecast to 2028

The global Doxorubicin Market is projected to reach US$ 1,983.40 million by 2028 from US$ 1,390.64 million in 2022; it is expected to register a CAGR of 6.1% from 2022 to 2028.

Increasing prevalence of cancer and increasing preference of chemotherapy are driving the global doxorubicin market growth. However, the potential side-effects associated with doxorubicin is hampering the global doxorubicin market growth.

Get Exclusive Sample PDF @: https://www.premiummarketinsights.com/sample/TIP00028146?utm_source=OpenPr&utm_medium=10640

Analysis of the Top Market Players:

1. Accord Healthcare
2. Cipla Inc.
3. Dr. Reddy's Laboratories
4. Meiji Holdings Co., Ltd.
5. Janssen Pharmaceuticals (Johnson and Johnson Services, Inc.)
6. Novartis AG
7. Pfizer Inc.
8. Sun Pharmaceutical Industries Ltd
9. Baxter International Inc.
10. Zydus Cadila

In this report, the market has been segmented on the basis of:

Drug Formulation (Lyophilized Powder and Doxorubicin Injection)
Application (Breast Cancer, Kidney Cancer, Liver Cancer, Sarcoma, Ovarian Cancer, Lung Cancer, Leukemia, Multiple Myeloma, and Others)
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

Access full Report Description, TOC, Table of Figure, Chart, etc. @: https://www.premiummarketinsights.com/reports-tip/doxorubicin-market

Doxorubicin belongs to the anthracycline family and is widely used for the treatment of malignancies such as breast, lung, multiple myeloma, ovarian, kidney, liver, sarcoma, and others. The product is used in the patients with cancer whose disease has progressed or recurred after chemotherapy. Cancer is a leading cause of death globally. According to the World Health Organization (WHO), cancer was the first leading cause of death in people below 70 years in 183 countries and the fourth major cause of death among the population of all ages in 123 countries worldwide in 2019. In addition, as per the data published by the WHO in March 2021, different cancer types will have caused ~10 million deaths in 2020. The increasing prevalence of cancer has burdened healthcare systems worldwide, bolstering the demand for chemotherapy. Doxorubicin is one of the primary drugs used as first-line treatment in chemotherapy.

The drug is used to cause regression in disseminated neoplastic diseases like breast, ovarian, transitional cell bladder, thyroid, gastric, acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas, Hodgkin's disease, malignant lymphoma, and bronchogenic carcinomas, in which the small cell histologic type. The drug is also recommended as adjuvant therapy in women who have had primary breast cancer removed and have axillary lymph node involvement.

Order a copy of this research report at @: https://www.premiummarketinsights.com/buy/TIP00028146?utm_source=OpenPr&utm_medium=10640

Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Ankit Mathur
Phone: +1-646-491-9876
Email: sales@premiummarketinsights.com

About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost-effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.
Premium Market Insights has an extensive coverage of industry reports, company reports and country reports across all industries. In case your research needs are not met by syndicated reports offered by leading publishers, we can help you by offering a customized research solution by liaising with different research agencies saving your valuable time and money.
We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider. We also offer enterprise subscriptions which provide significant cost savings to our clients.

This release was published on openPR.